Stiegeler N, Garsed D, Au-Yeung G, Bowtell D, Heinzelmann-Schwarz V, Zwimpfer T
Front Oncol. 2024; 14:1387281.
PMID: 38894867
PMC: 11183307.
DOI: 10.3389/fonc.2024.1387281.
Ping N, Zuo K, Cai J, Rong C, Yu Z, Zhang X
Front Pharmacol. 2024; 15:1362301.
PMID: 38746012
PMC: 11091408.
DOI: 10.3389/fphar.2024.1362301.
Zhang Y, Zheng J, Chen M, Zhao S, Ma R, Chen W
BMC Cancer. 2024; 24(1):519.
PMID: 38654216
PMC: 11040824.
DOI: 10.1186/s12885-024-12290-x.
Xiao M, Cui X, Xu C, Xin L, Zhao J, Yang S
CNS Neurosci Ther. 2024; 30(4):e14698.
PMID: 38600891
PMC: 11007544.
DOI: 10.1111/cns.14698.
Guarischi-Sousa R, Kroll J, Bonaldi A, Pierry P, Villela D, Souza C
Diagnostics (Basel). 2023; 13(21).
PMID: 37958189
PMC: 10648202.
DOI: 10.3390/diagnostics13213293.
DNA double-strand break genetic variants in patients with premature ovarian insufficiency.
Ding X, Gong X, Fan Y, Cao J, Zhao J, Zhang Y
J Ovarian Res. 2023; 16(1):135.
PMID: 37430352
PMC: 10332088.
DOI: 10.1186/s13048-023-01221-2.
Enzalutamide and olaparib synergistically suppress castration-resistant prostate cancer progression by promoting apoptosis through inhibiting nonhomologous end joining pathway.
Dong H, Zang P, Bao M, Zhou T, Ni C, Ding L
Asian J Androl. 2023; 25(6):687-694.
PMID: 37282383
PMC: 10715611.
DOI: 10.4103/aja202316.
Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology.
Panni U, Chen M, Zhang F, Cullinan D, Li L, James C
Cancer Immunol Immunother. 2023; 72(8):2813-2827.
PMID: 37179276
PMC: 10361914.
DOI: 10.1007/s00262-023-03463-x.
Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer.
Perez-Villatoro F, Oikkonen J, Casado J, Chernenko A, Gulhan D, Tumiati M
NPJ Precis Oncol. 2022; 6(1):96.
PMID: 36581696
PMC: 9800569.
DOI: 10.1038/s41698-022-00339-8.
HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data.
Wang X, Xu Y, Zhang Y, Wang S, Zhang X, Yi X
Front Genet. 2022; 13:990244.
PMID: 36246633
PMC: 9554509.
DOI: 10.3389/fgene.2022.990244.
Applications of Proteomics in Ovarian Cancer: Dawn of a New Era.
Ghose A, Gullapalli S, Chohan N, Bolina A, Moschetta M, Rassy E
Proteomes. 2022; 10(2).
PMID: 35645374
PMC: 9150001.
DOI: 10.3390/proteomes10020016.
DNA-PKcs-dependent phosphorylation of RECQL4 promotes NHEJ by stabilizing the NHEJ machinery at DNA double-strand breaks.
Lu H, Guan J, Wang S, Li G, Bohr V, Davis A
Nucleic Acids Res. 2022; 50(10):5635-5651.
PMID: 35580045
PMC: 9178012.
DOI: 10.1093/nar/gkac375.
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Luo L, Keyomarsi K
Expert Opin Investig Drugs. 2022; 31(6):607-631.
PMID: 35435784
PMC: 9296104.
DOI: 10.1080/13543784.2022.2067527.
HDAC Inhibitor Sodium Butyrate Attenuates the DNA Repair in Transformed but Not in Normal Fibroblasts.
Gnedina O, Morshneva A, Skvortsova E, Igotti M
Int J Mol Sci. 2022; 23(7).
PMID: 35408878
PMC: 8998589.
DOI: 10.3390/ijms23073517.
Role of Paralogue of XRCC4 and XLF in DNA Damage Repair and Cancer Development.
Tang J, Li Z, Wu Q, Irfan M, Li W, Liu X
Front Immunol. 2022; 13:852453.
PMID: 35309348
PMC: 8926060.
DOI: 10.3389/fimmu.2022.852453.
PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components.
OSullivan Coyne G, Karlovich C, Wilsker D, Voth A, Parchment R, Chen A
Onco Targets Ther. 2022; 15:165-180.
PMID: 35237050
PMC: 8885121.
DOI: 10.2147/OTT.S278092.
Targeted Cancer Therapy Based on Acetylation and Deacetylation of Key Proteins Involved in Double-Strand Break Repair.
Wang X, Zhao J
Cancer Manag Res. 2022; 14:259-271.
PMID: 35115826
PMC: 8800007.
DOI: 10.2147/CMAR.S346052.
The Role of Ku70 as a Cytosolic DNA Sensor in Innate Immunity and Beyond.
Sui H, Hao M, Chang W, Imamichi T
Front Cell Infect Microbiol. 2021; 11:761983.
PMID: 34746031
PMC: 8566972.
DOI: 10.3389/fcimb.2021.761983.
The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
Tao M, Wu X
J Exp Clin Cancer Res. 2021; 40(1):338.
PMID: 34702316
PMC: 8547054.
DOI: 10.1186/s13046-021-02139-7.
Progress in Gene-Editing Technology of Zebrafish.
Li Y, Jia Z, Zhang S, He X
Biomolecules. 2021; 11(9).
PMID: 34572513
PMC: 8468279.
DOI: 10.3390/biom11091300.